ArticleMaterials today. Bio2024
PEGylated Elesclomol@Cu(Ⅱ)-based Metal‒organic framework with effective nanozyme performance and cuproptosis induction efficacy for enhanced PD-L1-based immunotherapy.
Abstract read
In one paragraph
Article in Materials today. Bio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- NIR-II Type I AIE Photosensitiser-Functionalized MOF-Cu Nanoplatform Promotes Ferroptosis and Cuproptosis for Antitumor Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Immunoregulatory strategies of MOF-based nanodrug delivery systems: Advances in cancer therapy applications and future perspectives.Materials today. Bio · 2026Review
- PEG-GE11-modified nanoplatform for co-delivery of cisplatin and plumbagin in targeted therapy of oral squamous cell carcinoma.RSC advances · 2026Article
- Copper-based metal-organic frameworks: applications and prospects in cancer diagnosis and therapy.RSC advances · 2026Review
- Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities.Journal of hematology & oncology · 2026Review
- Harnessing Cuproptosis for Antitumor Immunity: A Review of Current Evidence and Therapeutic Strategies.Molecular carcinogenesis · 2026Review
- Mitochondria-targeted cuproptosis-driven nanoplatform for synergistic photothermal/chemodynamic therapy and systemic antitumor immunotherapy.Materials today. Bio · 2026Article
- Therapeutic horizons of cuproptosis: bibliometric mapping of copper-dependent cell death research and its pharmacological implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Metal-Organic Framework Nanozymes: From Rational Design and Synthesis to Biomedical Applications.Nano-micro letters · 2026Review
- Synergistic Activation of Immunogenic Cell Death and the cGAS-STING Pathway by Engineered Zinc/Manganese-Based Metal-Organic Framework Nanoplatforms for Colon Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cu-based metal-organic frameworks: synthesis, biomedical applications, and beyond.Discover nano · 2026Review
- Ambivalent Copper: Mechanistically Distinct Immune Effects Driving Innovation in Cancer Nanomedicine.Pharmaceutics · 2026Review
- Precise Catalysis and Immune Activation: New Strategies for Tumor Immunotherapy with Cascade Nanozymes.International journal of nanomedicine · 2026Review
- Nanozymes in Tumor Microenvironment Modulation for Cancer Therapy.Biomaterials research · 2026Review
- Harnessing copper: Innovative approaches to combat neurodegenerative diseases and cancer (Review).International journal of molecular medicine · 2026Review
- Cuproptosis-triggering nanomedicine boosts antitumor immunotherapy.Theranostics · 2026Review
- Emodin triggers cuproptosis to suppress hepatocellular carcinoma via SLC7A11/FDX1 axis.Frontiers in oncology · 2026Article
- Emerging versatile nanozymes for the therapeutic and diagnostic applications of diseases.Journal of translational medicine · 2025Review
- Progress and prospects of metal-based immunotherapy in breast cancer.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025Review
- An Fe(III)-covalent organic framework (COF)-sorafenib nanoplatform induces chemo-ferroptosis for enhanced hepatocellular carcinoma immunotherapy.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Xufeng LuZhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, Department of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Wenhai DengOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Shuaibin WangZhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, Department of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Shengsheng ZhaoZhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, Department of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Bingzi ZhuZhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, Department of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Binglong BaiZhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, Department of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Yiwen MaoDepartment of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Ji LinZhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, Department of Gastrointestinal Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Yongdong YiZhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, Department of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Zuoliang XieResearch Center of Basic Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Xiang WangZhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, Department of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Yongyong LuDepartment of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Xiufeng HuangZhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, Department of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Tao YouZhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, Department of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Xiaolei ChenZhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, Department of Gastrointestinal Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Weijian SunZhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, Department of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Xian ShenZhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, Department of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanozymes constitute a promising treatment strategy for antitumor therapy. However, the catalytic function of metal‒organic framework (MOF)-based nanozymes during cuproptosis remains unclear. In this study, a Cu(Ⅱ)-based MOF nanocomposite loaded with the copper ionophore elesclomol and surface modified with polyethylene glycol polymer (PEG) was developed (ES@Cu(Ⅱ)-MOF) for effective cuproptosis induction. The peroxidase (POD)-like activity of ES@Cu(Ⅱ)-MOF generated an abundance of hydroxyl radicals (•OH) via a Fenton-like reaction, and its glutathione peroxidase (GSH-Px)-like activity converted Cu
Indexed as
Anti-PD-L1 antibodyBreast cancerCu(Ⅱ)-MOFCuproptosisImmunotherapyNanozyme
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.